Endometrial carcinoma: current concepts and future perspectives.
Endometrial carcinoma is increasing worldwide and, in most of western Europe and the U.S., it is now the most common malignancy in the female pelvis. The most common parameters in deciding therapy are staging, according to the International Federation of Gynecologists and Obstetricians (FIGO) and histopathological grading, and evaluation of myometrial invasion. The treatment results in terms of a 5-year survival rate, are about 90% for well and moderately differentiated stage I to II endometrial carcinomas, whereas that for poorly differentiated ones is about 70%. The latter figures point towards the need for further prognostic parameters to identify subgroups with a fatal form of the disease. One such parameter might be the concentration of steroid receptors and promising results have been published recently but still better prognostic parameters have been proposed recently. It is known that the DNA content in individual tumor cells is a prognostic parameter. Due to the development of flow cytometry such determinations are rapid and more precise, and the prognostic significance has been proved to be superior to the more commonly used parameters.